Professor Michael Hofman honoured with the Ramaciotti Medal for Excellence
10 December 2025
Peter Mac’s Professor Michael Hofman, has received the prestigious 2025 Ramaciotti Medal for Excellence in Biomedical Research award.
The Ramaciotti Medal is an annual award to honour an individual who has made an outstanding discovery in clinical or experimental biomedical research that has had an important impact on biomedical science, clinical science, or the way in which healthcare is delivered.
Professor Hofman has been instrumental in changing the way prostate cancer is detected and treated globally and has helped countless men receive the novel PSMA radioligand treatment ahead of approval through clinical trials he’s led at Peter Mac.
“I am truly honoured to be recognised as the Ramaciotti Medal for Excellence recipient in 2025,” Professor Hofman, a Nuclear Medicine Physician and Director of Peter Mac’s Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), said.
“Imaging and treatment of prostate cancer has changed markedly because of the research we have conducted with PSMA imaging and therapy, here at Peter Mac.
“These transformational technologies have been adopted globally, resulting in improved outcomes for patients”.
“Our Prostate Cancer Theranostics and Imaging Centre of Excellence has pioneered clinical trials through the establishment of a multidisciplinary team of nuclear medicine, medical oncology, urology, radiation oncologists and radiopharmaceutical scientists that is unparalleled globally.”
Professor Hofman noted that in 2014, there were only two facilities in Australia performing PSMA PET/CT while today, there are more than 100 PET/CT scanners around Australia.
Professor Hofman has published 350 manuscripts with over 25,000 citations, with 5 landmark papers in the last 5 years having over 1000 citations each. He has won several prestigious awards, including the 2025 RACP Foundation Eric Susman Prize, 2025 University of Melbourne Marles Medal and the Society of Nuclear Medicine and Molecular Imaging Saul Hertz Award in 2024. Along with the Ramaciotti Medal he also received $50,000.
Professor Hofman has been listed by Clarivate (Thomson Reuters) as one of the world’s most influential scientists in 2025. He was also named Australia’s best nuclear medicine researcher for the last three years.
He has been awarded over $50 million in research funding as the primary chief investigator and serves as an inaugural scientific member of the Australasian Radiopharmaceutical Trial Network (ARTnet), fostering the conduct of multi-centre clinical trials in Australia.